STAT July 26, 2022
Kira Sampson, Carlise Sorenson and Kate Adamala

Expanding new medical treatments requires pushing — and sometimes breaking — the boundaries of what currently defines therapeutics. One of those boundaries is the very definition of a cell.

Until recently, cells were all-natural beings, living cell begetting living cell. That’s changing as synthetic biologists and engineers are learning to create synthetic cells that may someday change how a range of diseases are treated.

Synthetic cells are membrane-enclosed systems constructed from nonliving parts. They can contain engineered genomes, artificial organelles, and complex enzyme pathways. Acting as microscopic bioreactors, they present opportunities to design and deliver medicines that uniquely match an individual’s DNA and disease profile.

Researchers across the U.S. and around the globe are advancing the understanding, development, and use...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA approves Lumicell’s breast cancer imaging tool
Boehringer Ingelheim Strikes Regenerative Med R&D Deal Spanning MASH & More Liver Diseases
Opinion: An FDA pathway can accelerate innovation for Duchenne muscular dystrophy
What principles should guide artificial intelligence innovation in healthcare?
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer

Share This Article